Clinical trials · Chicago, IL
Cancer clinical trials in Chicago
We’re tracking 622 recruiting cancer studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06671613Recruiting
Fasting-mimicking diet with immunotherapy for advanced lung cancer
This study combines a special periodic diet that mimics fasting with the standard immunotherapy drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer. The goal is to see if the diet can help the immunotherapy work better.
Chicago, IllinoisAges 18 years+ - NCT01120353Recruiting
Childhood cancer survivors study to understand long-term health
This study follows people who survived certain childhood cancers to learn what long-term health effects may happen after treatment. It also compares survivors with siblings to help researchers understand differences that may be related to cancer or treatment.
Chicago, IllinoisAges Any age - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Chicago, IllinoisAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Chicago, IllinoisAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Chicago, IllinoisAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Chicago, IllinoisAges 18 years+ - NCT06057935RecruitingPhase 2
Extra chemotherapy after surgery for peritoneal mesothelioma
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
Chicago, IllinoisAges 18 years+ - NCT07290621RecruitingPhase 2
Toripalimab with standard treatment for HPV-positive throat cancer
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
Chicago, IllinoisAges 18 years+ - NCT06824818Recruiting
Can older men stop prostate cancer treatment early?
This study looks at whether men aged 70 or older who have been on hormone therapy for over 3 years can safely stop treatment. It aims to find out if stopping early helps maintain quality of life without letting the cancer come back.
Chicago, IllinoisAges 70 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Chicago, IllinoisAges 18 years+ - NCT03998202Recruiting
Study of chemotherapy side effects in older colorectal cancer patients
This study looks at how chemotherapy and immunotherapy affect the body in older adults with colorectal cancer, especially early side effects. It may help researchers understand why some people lose strength and how to better predict and manage treatment toxicity.
Chicago, IllinoisAges 60 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Chicago, IllinoisAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Chicago, IllinoisAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Chicago, IllinoisAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Chicago, IllinoisAges 18 years+ - NCT05001880RecruitingPhase 2
Chemo with or without immunotherapy for peritoneal mesothelioma
This study tests whether adding immunotherapy to standard chemotherapy helps people with peritoneal mesothelioma, a cancer in the lining of the abdomen. You may receive chemotherapy alone or with immunotherapy, and the goal is to improve cancer control.
Chicago, IllinoisAges 18 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Chicago, IllinoisAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Chicago, IllinoisAges Any age - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT06055439RecruitingPhase 1/Phase 2
CAR T cell therapy for GI cancers
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
Chicago, IllinoisAges 18–85 - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Chicago, IllinoisAges 18 years+ - NCT07354100RecruitingPhase 1/Phase 2
Lactulose to boost gut health during immunotherapy
This study tests whether a simple sugar syrup called lactulose can improve gut health and make immunotherapy work better for certain cancers. Lactulose is taken by mouth along with your regular immunotherapy.
Chicago, IllinoisAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Chicago, IllinoisAges 18 years+
Hear when a new Cancer trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting cancer studies listed above.
- Northwestern University · 5 studies
- University of Chicago · 4 studies
- University of Chicago Comprehensive Cancer Center · 4 studies
- Research Site · 3 studies
- UC Comprehensive Cancer Center at Silver Cross · 3 studies
- University of Chicago Medicine Comprehensive Cancer Center · 3 studies
- University of Chicago Medicine-Orland Park · 3 studies
- Northwestern Medicine Cancer Center Delnor · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Illinois.
Common questions
- Are there cancer clinical trials near Chicago?
- Yes. We're currently tracking 622 recruiting cancer studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.